NASDAQ (usa) |
![]() |
6715.56 | -12.11 | -0.18% |
FTSE 100 (london) |
![]() |
7487.96 | -5.12 | -0.07% |
DAX (german) |
![]() |
13465.51 | 235.94 | 1.78% |
NIKKEI 225 (japan) |
![]() |
22420.08 | 408.47 | 1.86% |
Hang - Seng (hong kong) |
![]() |
28594.06 | 348.52 | 1.23% |
NIFTY - 50 (india) | ||||
Straits Times (singapore) |
![]() |
3391.61 | 17.53 | 0.52% |
KOSPI (korea) |
![]() |
2556.47 | 33.04 | 1.31% |
All Ordinaries (australia) |
![]() |
6005.30 | 28.90 | 0.48% |
BOVESPA (brazil) |
![]() |
74092.76 | -215.73 | -0.29% |
Resverlogix Corp (F: RFS)
RFS Technical Analysis
5
As on 28th Mar 2025 RFS STOCK Price closed @ 0.02 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.04 & Strong Sell for SHORT-TERM with Stoploss of 0.04 we also expect STOCK to react on Following IMPORTANT LEVELS. |
RFSSTOCK Price
Open | 0.02 | Change | Price | % |
High | 0.02 | 1 Day | -0.01 | -33.33 |
Low | 0.02 | 1 Week | -0.01 | -33.33 |
Close | 0.02 | 1 Month | -0.01 | -33.33 |
Volume | N/A | 1 Year | -0.02 | -50.00 |
52 Week High 0.06 | 52 Week Low 0.02 |
F Germany Most Active Stocks
IMU | 0.10 | -99.65% |
IMU | 0.10 | -99.65% |
IMU | 0.10 | -99.65% |
IMU | 0.10 | -99.65% |
IMU | 0.10 | -99.65% |
ENB | 47.60 | -0.92% |
TEF | 3.84 | -0.52% |
TEF | 3.84 | -0.52% |
WHL | 5150.00 | -0.44% |
WDI | 0.05 | -37.50% |
F Germany Top Gainers Stocks
F Germany Top Losers Stocks
RFS Daily Charts |
RFS Intraday Charts |
Whats New @ Bazaartrend |
RFS Free Analysis |
|
RFS Important Levels Intraday
RESISTANCE | 0.02 |
RESISTANCE | 0.02 |
RESISTANCE | 0.02 |
RESISTANCE | 0.02 |
RESISTANCE | 0.02 |
RESISTANCE | 0.02 |
RESISTANCE | 0.02 |
RESISTANCE | 0.02 |
RFS Forecast April 2025
4th UP Forecast | 0.04 |
3rd UP Forecast | 0.03 |
2nd UP Forecast | 0.03 |
1st UP Forecast | 0.03 |
1st DOWN Forecast | 0.01 |
2nd DOWN Forecast | 0.01 |
3rd DOWN Forecast | 0.01 |
4th DOWN Forecast | 0 |
RFS Weekly Forecast
4th UP Forecast | 0.02 |
3rd UP Forecast | 0.02 |
2nd UP Forecast | 0.02 |
1st UP Forecast | 0.02 |
1st DOWN Forecast | 0.02 |
2nd DOWN Forecast | 0.02 |
3rd DOWN Forecast | 0.02 |
4th DOWN Forecast | 0.02 |
RFS Forecast2025
4th UP Forecast | 0.1 |
3rd UP Forecast | 0.07 |
2nd UP Forecast | 0.06 |
1st UP Forecast | 0.04 |
1st DOWN Forecast | -0 |
2nd DOWN Forecast | -0.02 |
3rd DOWN Forecast | -0.03 |
4th DOWN Forecast | -0.06 |
Resverlogix Corp ( F Germany Symbol : RFS )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
RFS Other Details
Segment | EQ | |
Market Capital | 86207960.00 | |
Sector | Healthcare | |
Industry | Biotechnology | |
Offical website | > echo $website ; ?> |
RFS Address
![]() |
RFS Latest News
RFS Business Profile
Resverlogix Corp. operates as a late-stage clinical biotechnology company. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular, end-stage renal, chronic kidney, neurodegenerative, fabry, peripheral artery, and other orphan diseases, as well as diabetes mellitus. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the initial commercialization of apabetalone for Covid-19 in the United States and Canada. The company is headquartered in Calgary, Canada. Address: 4820 Richard Road SW, Calgary, AB, Canada, T3E 6L1
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service